Pelabresib for Myelofibrosis: BET Inhibition Enters Late-Stage Clinical Development
Pelabresib has reached Phase 3 trials for myelofibrosis, marking the first BET bromodomain inhibitor to approach potential FDA approval in epigenetic therapy.
Category Archives: Epigenetics
DOT1L and G9a/EHMT2 Inhibitors: Emerging Targets in Histone Methylation
Discover histone methylation inhibitors targeting DOT1L (H3K79) and G9a (H3K9). Understand pinometostat, UNC0638, and their disease implications.
DNMT Inhibitors: Decitabine, Azacitidine, and Next-Generation DNA Methyltransferase Targeting
Explore DNMT inhibitors for epigenetic research. Understand decitabine and azacitidine mechanisms, clinical use in MDS/AML, and resistance strategies.
BET Bromodomain Inhibitors: JQ1, I-BET, and Beyond – Targeting Transcriptional Regulators
Comprehensive guide to BET bromodomain inhibitors. Understand JQ1 and I-BET mechanisms, selectivity, resistance, and next-generation approaches.
EZH2 Inhibitors: Targeting the Epigenetic Silencer in Cancer and Immunotherapy
EZH2 inhibitors like tazemetostat target the Polycomb Repressive Complex 2, offering new therapeutic options in lymphoma and solid tumors. Discover mechanisms, combinations with immunotherapy, and tool compounds.
HDAC Inhibitors: A Researcher’s Guide to Choosing the Right Compound for Your Experiment
Comprehensive guide to HDAC inhibitor selection: pan-inhibitors, class-selective compounds, and isoform-specific tools for epigenetics research. Learn how to match inhibitors to your experimental questions.
